GlassScriptPhysician profile
Philip Myers
NPI 1518932672
$3,484.66
in general payments reported to CMS, 2019-2025
32 companies · $188 in 2025
The $188 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $555 · 2020: $299 · 2021: $705 · 2022: $617 · 2023: $657 · 2024: $463 · 2025: $188.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,308.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,308.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $586.14 | 2021-2025 | |
| Pfizer INC. | $504.69 | 2019-2025 | |
| Novo Nordisk INC | $481.72 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Daiichi Sankyo INC. | $294.59 | 2019-2024 | Injectafer |
| Lilly USA, LLC | $217.83 | 2019-2024 | Mounjaro, Zepbound |
| Merck Sharp & Dohme LLC | $191.83 | 2019-2023 | Belsomra |
| Abbott Laboratories | $150.64 | 2021-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $121.54 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $108.40 | 2021-2025 | Xifaxan, Trulance |
| Depuy Synthes Sales INC. | $83.46 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $81.24 | 2019-2024 | Breztri, Airsupra |
| Exact Sciences Corporation | $70.56 | 2023-2024 | Cologuard Collection Kit |
| Sanofi Pasteur INC. | $51.65 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $50.07 | 2019-2020 | |
| Astellas Pharma US INC | $49.92 | 2024-2025 | Veozah |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $48.80 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $44.38 | 2021-2024 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $40.97 | 2023 | |
| Janssen Pharmaceuticals, INC | $40.49 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $37.65 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $36.41 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.02 | 2019 | |
| Shire North American Group INC | $24.84 | 2019 | |
| Alexion Pharmaceuticals, INC. | $24.64 | 2021 | |
| Idorsia Pharmaceuticals US INC | $20.83 | 2023 | Quviviq |
| Eisai INC. | $19.65 | 2020 | |
| Hologic Sales and Service, LLC | $15.68 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $14.76 | 2023 | Eliquis |
| Smith+Nephew, INC. | $13.24 | 2019 | |
| Vertos Medical, INC. | $12.23 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $10.81 | 2019 | |
| Dynavax Technologies Corporation | $5.98 | 2023 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Myers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.